Endocrine Abstracts

Background: Liraglutide is a long-acting glucagon-like peptide-1(GLP-1) receptor agonist that promotes weight loss. The minimum adequate/good response to liraglutide (≥5% weight loss at 3 months) is not achievable in all patients. Currently there are no biomarkers to predict good response. Enhanced postprandial glicentin concentration was recently considered as superior to GLP-1 in predicting weight loss following bariatric surgeries.Objective 1) T...

Background: Bariatric surgery, dietary restriction and gut hormones treatment for obesity, lead to distinctive changes in weight-loss maintenance and glycaemia. We previously showed that Roux-en-Y Gastric Bypass (RYGB) and Very-Low-Calorie-Diet (VLCD) were superior in weight-loss, compared to a tripeptide hormone infusion of G lucagon-like Peptide-1, O xyntomodulin and P eptide-YY over a month (GOP, infused at doses to replicate their peak post-prandial concen...